TUXARIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tuxarin, and when can generic versions of Tuxarin launch?
Tuxarin is a drug marketed by Mainpointe and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in TUXARIN is chlorpheniramine maleate; codeine phosphate. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the chlorpheniramine maleate; codeine phosphate profile page.
DrugPatentWatch® Generic Entry Outlook for Tuxarin
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TUXARIN?
- What are the global sales for TUXARIN?
- What is Average Wholesale Price for TUXARIN?
Summary for TUXARIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in TUXARIN? | TUXARIN excipients list |
| DailyMed Link: | TUXARIN at DailyMed |
US Patents and Regulatory Information for TUXARIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | RX | No | No | 9,066,942 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mainpointe | TUXARIN ER | chlorpheniramine maleate; codeine phosphate | TABLET, EXTENDED RELEASE;ORAL | 206323-001 | Jun 22, 2015 | RX | No | No | 9,107,921 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
